Vertex（福泰制药）将于11月2日公布2026年第三季度财务业绩
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Vertex Pharmaceuticals（Nasdaq: VRTX）将于2026年11月2日美股收盘后公布2026年第三季度财务业绩，并于美东时间下午4:30举行电话会议和网络直播。公司已获批疗法覆盖囊性纤维化、镰状细胞病、输血依赖型β地中海贫血、急性疼痛和肢端肥大症，并继续推进IgA肾病、神经病理性疼痛、APOL1介导的肾病等临床项目。
BOSTON--(BUSINESS WIRE)--Oct. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.”
The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
(VRTX-WEB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20261007119271/en/
Vertex Pharmaceuticals Incorporated Investor Relations
Source: Vertex Pharmaceuticals Incorporated
来源：Vertex Pharmaceuticals｜福泰制药 · investors.vrtx.com